Clinical Trials Logo

Skin Wound clinical trials

View clinical trials related to Skin Wound.

Filter by:

NCT ID: NCT03649308 Active, not recruiting - Wound Heal Clinical Trials

Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting

TRUTH
Start date: September 19, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to compare negative pressure wound therapy to traditional care after split-thickness skin grafting in patients aged over 18.

NCT ID: NCT03394612 Active, not recruiting - Skin Wound Clinical Trials

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

Start date: February 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in adults and children with full-thickness Skin defects.

NCT ID: NCT03005054 Terminated - Burns Clinical Trials

StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

Start date: April 24, 2017
Phase: Phase 2
Study type: Interventional

About 20 participants will be enrolled in this trial if they have had an accident that damages both the dermal (outside) and epidermal (inside) layers of skin on up to 49% of their body. This condition is called full-thickness complex skin defects resulting from acute traumatic skin loss. Participants will be treated with StrataGraft skin tissue to evaluate it's safety and effectiveness for use in treating full-thickness complex skin defects.

NCT ID: NCT01437852 Completed - Burns Clinical Trials

StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin defects including a deep partial-thickness component resulting from thermal injury. The study has been designed to focus on the evaluation of safety and tolerability of prolonged exposure to increasing amounts of a single application of StrataGraft skin tissue, while also assessing the potential for StrataGraft tissue to promote healing of the deep partial-thickness component of these complex skin defects as an alternative to donor site harvesting and autografting. Targeted enrollment for this study is up to 30 patients with complex skin defects due to thermal burns which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in the operating room just prior to grafting.